Earnings Call Transcript Q1FY27

Registered Office: 103, Akruti Arcade, Opposite A H Wadia High School, Near Azad Nagar Metro Station, Andheri (West), Mumbai –400058. Tel: 022 61437991 | Email: info@laxmidentallimited.com | Website: www.laxmidentallimited.com CIN No: L51507MH2004PLC147394 | GST No: 27AABCL0001A1ZL Date: August 19, 2026 Listing Department Listing & Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mumbai – 400001 Plot No. C/1, “G” Block BSE Scrip Code: 544339 Bandra-Kurla Complex Bandra (E), Mumbai – 400 051 Symbol: LAXMIDENTL Re: LAXMI DENTAL LIMITED - ISIN: INE0WO601020 Dear Sir(s)/Madam(s), Sub: - Transcript of the Q1FY27 Earnings Conference Call of Laxmi Dental Limited (“Company”). Further to our intimations dated August 7, 2026 and August 12, 2026 and pursuant to the provisions of Regulation 30 read with Schedule III Part A Para A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI Listing Regulations”), we are enclosing the Transcript of the ‘Q1FY27 Earnings Conference Call’ (i.e., Post Earnings/Quarterly Call), held on Wednesday, August 12, 2026 at 11:00 A.M. (IST), wherein, inter-alia, the unaudited financial results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, were discussed. The aforementioned transcript of the ‘Q1FY27 Earnings Conference Call’ (i.e., Post Earnings/Quarterly Call) is also uploaded on the Company’s website at https://laxmidentallimited.com/for-investors. Kindly take the above on record. Thanking you, For Laxmi Dental Limited -------------------------------------------------- Suman Saha Company Secretary and Compliance Officer ICSI Membership Number: A33035 Encl.: As above. “Laxmi Dental Limited Q1 FY27 Earnings Conference Call” August 12, 2026 “E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recordings uploaded on the stock exchange on August 12, 2026, will prevail.” MANAGEMENT: MR. SAMEER MERCHANT – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – LAXMI DENTAL LIMITED MR. DHARMESH DATTANI – CHIEF FINANCIAL OFFICER – LAXMI DENTAL LIMITED Page 1 of 14 Laxmi Dental Limited August 12, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Laxmi Dental Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the management's opening remarks. Should you need assistance during this conference call, please signal the operator by pressing star then zero on your touch-tone telephone. Please note that this conference is being recorded. Before we begin, a brief disclaimer. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on the date of this call. These statements are not the guarantee of future performance of the company and it may involve risk and uncertainties that are difficult to predict. I will now hand the conference over to Mr. Sameer Merchant, Managing Director and CEO. Thank you and over to you, sir. Sameer Merchant: Thank you. Good morning, everyone. A warm welcome to all of you and thank you for joining our earnings call. On this call, we are joined by our CFO, Mr. Dharmesh Dattani, and Strategic Growth Advisors, our Investor Relation Advisors. The result and the presentation are uploaded on the stock exchange and company website. I hope everybody has had a chance to look at them. I am pleased to share that Q1 FY27 was a strong quarter for us, with broad-based growth across our dental laboratory and aligner solutions, providing a healthy start to the year. Our revenue for Q1 FY27 stood at approximately INR75 crores, registering a y-o-y growth of 13.9%. This was our highest ever quarterly revenue. During the quarter, we witnessed a healthy improvement in profitability, largely driven by a favourable product mix. EBITDA grew by 20.6% y-o-y with margins improving to 19.2%, while PAT increased by 23.8% y-o-y with margins standing at 13.8%. Coming to our segmental performance, our dental lab business delivered another strong quarter with revenue growing at 23.5% y-o-y, driven by healthy performance across both domestic and international markets. Notably, the international business registered an impressive growth of 37.4% year-on-year. This momentum reflects the strong relationship and market presence we have built across global markets over the years. We are also looking forward to participating in the International Dental Show towards the end of the fiscal year. The IDS, known as the International Dental Show, is one of the world's premier dental exhibitions which happens every two years, which provides an excellent platform to showcase our products to dental laboratories, companies, and distributors from across the globe. It is also a great learning platform where we get to explore new technologies and innovative products that can be added to our portfolio. It is one of the few activities that helps us build better networks in the international markets. I would also like to highlight that we have recently appointed a new CEO to head our USA business. Based in the USA, he brings over 32 years of experience in medical devices and dental industry. Page 2 of 14 Laxmi Dental Limited August 12, 2026 His appointment will strengthen our on-ground leadership, enable a more market-focused strategy tailored towards the US region, and support the continued scaling in one of our key international markets. Our aligner solution business also delivered another strong quarter, recording a healthy 28.6% year-on-year growth. With this segment, Bizdent grew by 27.8% year-on-year, while Vedia registered a 29.3% year-on-year increase. These numbers reflect the effectiveness of our strategy for delivering sustainable and profitable growth. Such strong performance across all segments is attributed to our sustained efforts of our sales and ops team, supported by initiatives such as scanner deployment in the past, promotional activities, training programs, participation in dental events, and ongoing AI-related projects. Industry-wide, we see strong adoption of scanners in line with global trends. We continuously evaluate our scanner roadmap in line with technological advancements and innovations showcased at leading global dental exhibitions. Our paediatric dental business, Kids-e-Dental, continued its strong growth trajectory, delivering an impressive 54.4% year-on-year growth during this quarter as the business is steadily scaling up. In FY27, we plan to make investments towards the addition of new machinery to modernize and expand the capacity of our manufacturing capabilities. These investments are aimed at supporting long-term growth while enhancing operational efficiencies across our business segments. We have also executed a letter of intent to acquire a new land situated in Palghar, Maharashtra. This is towards transitioning from our currently leased premises to a newly owned facility, which will enable us to improve the workflow efficiency and better control the cost structure. Further, it will also support the future scalability of our business. We will share further updates on this matter as and when there is progress. Going forward, we continue to execute our strategy centred around expanding our market reach, driving product innovation, accelerating digitalization, and building a trusted and well- recognized brand in the dental industry. With this, we remain confident in delivering sustainable and long-term profitable growth. I will now hand it over to our CFO, Mr. Dharmesh Dattani, to take it forward. Thank you. Dharmesh Dattani: Thank you. Thank you, Sameer bhai. Let me give a glance at our consolidated financial performance during Q1 FY27. Revenue from opera [Showing first 8,000 characters — download PDF for full document]